Isatuximab in Combination With Novel Agents

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

What's the purpose of the trial?

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
258
Last Updated
1 month ago
Patient Screener

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Belantamab Mafodotin is an antibody-drug conjugate (ADC) that binds to BCMA on tumor cell surfaces. Belantamab Mafodotin is used in the treatment of multiple myeloma.  
  • Belumosudil mesylate is a kind of drug called a kinase inhibitor. Belumosudil mesylate is often used in the treatment of chronic graft versus host disease.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Evorpacept is a checkpoint inhibitor targeting CD-47 that is being studied for use in several different indications.
  • Isatuximab is a type of drug called a monoclonal antibody. Isatuximab targets a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Pegenzileukin (SAR444245)
  • Pomalidomide is a kind of medication called an immunomodulatory agent that promotes an immune response to help slow tumor growth. Pomalidomide is used in the treatment of several different indications.
  • SAR439459

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Substudy 01

Accepting patients

Substudy 02

Accepting patients

Substudy 03

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.